Notice is hereby given that ORI has taken final action in the following case:
Based on the Respondent’s acceptance of ORI’s research misconduct findings, ORI found that Sheng Wang, PhD, who has been an Asst Prof, Dept of Medicine, Boston University School of Medicine Cancer Research Center, engaged in research misconduct in research supported by R01CA102940 and R01CA101992.
ORI found that the Respondent engaged in research misconduct by fabricating data that were included in 2 published papers:
1. Zhang, B., Faller, D.V., Wang, S. “HIC1 regulates tumor cell responses to endocrine therapies.’ Mol. Endocrinol. 23(12):2075-85, 2009; and
2. Zhang, B., Chambers, K.J., Leprince, D., Faller, D.V., Wang, S. “Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control.’ Oncogene 28(5):651-61, 2009.
Specifically, ORI found that Respondent:
Fabricated RT-PCR and ChIP experiments represented in Figures 1b, 2b, 3a,b, 4b,c, 6a,b, 7c in Mol. Endocrinol. 23(12):2075-85, 2009; RT-PCR and/or ChIP experiments were included in 6 of 7 figures in this publication; and
Fabricated RT-PCR and ChIP experiments represented in Figures 2a,b, 3a,b, 4a,c, 5a,b, 6b,c, 8a,b in Oncogene 28(5):651-61, 2009; RT-PCR and/or ChIP experiments were included in 6 of 8 figures in this publication.
Respondent has entered into a Voluntary Exclusion Agreement. Respondent and the U.S. PHS want to conclude this matter without further expenditure of time or other resources. Respondent accepts ORI’s findings of research misconduct as set forth above but neither admits nor denies committing research misconduct. The Agreement does not constitute an admission of liability on Respondent’s part. Respondent agrees not to appeal the jurisdiction of ORI or request a U.S. DHHS administrative hearing to review the findings as set forth in the Agreement.
As a condition of the Agreement, Respondent agrees that the Mol. Endocrinol. 23(12):2075-85, 2009, and Oncogene 28(5):651-61, 2009, publications be retracted.
In entering into the Agreement, Dr. Wang has voluntarily agreed for a period of 2 years, beginning on July 18, 2011:
(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government …; and
(2) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.